Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 17/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889 | 0.86 | LIPE (0.64) | LIPEEGLN1 | |
| SCHEMBL11294 | 0.86 | LIPE (0.64) | LIPEEGLN1 | |
| SCHEMBL11679 | 0.86 | LIPE (0.64) | LIPEEGLN1 | |
| SCHEMBL12723935 | 0.84 | LIPE (0.60) | LIPEEGLN1 | |
| SCHEMBL5345 | 0.84 | LIPE (0.60) | LIPEEGLN1 | |
| SCHEMBL1589343 | 0.83 | LIPE (0.59) | LIPEEGLN1KMT2A | |
| SCHEMBL10123 | 0.83 | LIPE (0.65) | LIPEEGLN1 | |
| SCHEMBL12447326 | 0.83 | LIPE (0.59) | LIPEEGLN1KMT2A | |
| SCHEMBL5755 | 0.83 | LIPE (0.59) | LIPEEGLN1KMT2A | |
| SCHEMBL10124 | 0.83 | LIPE (0.65) | LIPEEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688881-B1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2488493-B1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8703807-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2688881-A1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2686300-A1 | NEW AZASPIRODECANONE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120245191-A1 | NEW AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
| WO-2012123468-A1 | NEW AZASPIRODECANONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | CYP51A1, HSD17B7, NR5A1 | LIPE 4568/4885EGLN1 1268/4885KMT2A 1226/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | LIPE 3/4885EGLN1 815/4885KMT2A 4540/4885 |
| US-20120245191-A1 | NEW AZASPIRODECANONE COMPOUNDS | TYMS, CDK11A, CDKN1A | LIPE 4854/4885EGLN1 1190/4885KMT2A 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.